The short answer. “Grey market tirzepatide” (or gray market; the spelling changes nothing) is tirzepatide sold with no prescription, no pharmacist, and no pharmacy you can look up: usually a vial labeled “research use only” from a peptide website, a group chat, or a social media seller. The FDA calls those labels false when the product is marketed for injection and has told sellers these are unapproved new drugs. Licensed compounding is also not FDA-approved, but it runs inside a system with a U.S.-licensed clinician, a licensed pharmacy named on the label, and a state board that can inspect it. If you are already using a grey-market product, the safer route is below; it does not require you to start over.
A lot of what gets sold online in 2026 as “compounded GLP-1” isn’t coming from a U.S.-licensed pharmacy at all. It’s coming from grey-market channels — vendors operating outside the prescription and pharmacy-licensure system entirely — and the FDA has been actively targeting this category through warning letters and import restrictions for more than a year now.
The problem for patients is that both categories can look nearly identical on a landing page. A well-designed website, a checkout flow, a product photo of a labeled vial — none of that tells you whether what’s behind it is a state-licensed compounding pharmacy filling a valid prescription, or an unregulated seller shipping a product with no clinician involved at any point. Compounded medications are not FDA-approved products, full stop — that's true whether they come from a properly licensed pharmacy or a grey-market source. But the regulatory gap between those two sources is enormous, and it's the gap this guide is built to help you see.
Below is the framework: what licensed compounding actually is, what grey-market GLP-1 actually is, why the FDA treats the difference as a safety issue rather than a technicality, and a practical checklist you can use before you order anything.
- Import Alert 66-80, the GLP-1 "green list," was republished October 9, 2026. FDA established it in September 2025; GLP-1 active ingredients from facilities FDA has evaluated clear the border, and "all other GLP-1 APIs from unverified foreign sources may be subject to automatic detention" (FDA Import Alert 66-80; National Law Review). Grey-market vendors that relied on unverified imported powder are the target.
- A licensed Houston pharmacy's compounded tirzepatide vials were recalled. FDA issued Houston Rx LLC a Form 483 on August 28, 2026 (FDA compounding actions); Medical Daily reported 14 inspection observations, including exposed skin in sterile areas and research-grade ingredients. The lesson is not "compounding is unsafe"; it is that a license is the start of vetting, not the end.
- Two new companion pages: how to vet a compounding pharmacy, the 7-point checklist, and is compounded tirzepatide legal, and how to tell what you actually have.
What “Licensed Compounding” Actually Means (503A vs 503B)
Compounding is the practice of a pharmacy preparing a customized medication for a patient, typically when a commercially manufactured product doesn't fit that patient's specific clinical situation. The FDA regulates two distinct categories of legal compounding, and understanding the difference is the foundation of this entire topic. The agency's policy update on compounders as the national GLP-1 supply stabilized lays out the current framework in detail.
503A pharmacies are state-licensed pharmacies that compound patient-specific prescriptions. A 503A pharmacy prepares a medication only after receiving a valid prescription from a licensed clinician for a named, individual patient. These pharmacies are licensed and inspected at the state level through their state board of pharmacy.
503B outsourcing facilities are a separate category: federally registered facilities that can compound in larger batches, under a higher tier of FDA oversight, and can supply to clinics and practices rather than only to a single named patient at a time.
Both categories are legally distinct from the grey market, and both share one non-negotiable requirement: a valid prescription from a U.S.-licensed clinician tied to a real patient. Neither 503A nor 503B compounding means a product is FDA-approved — compounded drugs, by definition, have not gone through the FDA's premarket approval process. What licensure means is that the pharmacy is operating inside a known, inspectable regulatory system, rather than outside of it.
The FDA's compounding framework also changed materially in 2025. Semaglutide came off the 503A drug shortage list on April 22, 2025, and off the 503B list on May 22, 2025. Tirzepatide came off the 503A list on February 18, 2025, and off the 503B list on March 19, 2025, according to the FDA's compounder policy update. Once a drug is off the shortage list, mass compounding of essentially copycat versions is no longer permissible under the shortage exemption — compounding for an individual patient's documented clinical need under 503A can still occur under narrower conditions. This shift is part of why the market has fragmented, and part of why grey-market sourcing has become more visible.
What “Grey-Market Tirzepatide” (and Grey-Market GLP-1) Actually Means
Grey-market GLP-1 refers to semaglutide, tirzepatide, or related compounds sold outside the licensed pharmacy and prescription system altogether. It is not the same category as licensed 503A or 503B compounding, even when a seller uses similar language on a website.
Common characteristics of grey-market GLP-1 sourcing include:
- No prescription requirement. Product ships directly to the buyer without any clinician reviewing the order.
- No licensed pharmacy involved. There is no compounding pharmacy of record, no pharmacist verifying the preparation, and nothing to look up on a state board of pharmacy website.
- Foreign-sourced active pharmaceutical ingredient (API). The raw material frequently comes from manufacturers that are not on the FDA's approved supplier list for these ingredients.
- Mislabeling as a workaround. Vials are often labeled “for research use only” or “not for human consumption” — language that attempts to sidestep drug regulations while the product is being marketed and used as an injectable weight-loss drug.
In September 2025, the FDA implemented the Green List of Import Alert 66-80, which lets the agency detain shipments of GLP-1 active pharmaceutical ingredient at the border unless the manufacturer and product are on an approved “Green List”; the alert was most recently revised on October 9, 2026. The FDA's own description is that the alert exists to keep poor-quality foreign-made ingredient out of the U.S. supply chain, and that it does not limit legal compounding from compliant suppliers. It was aimed squarely at the foreign-API pipeline that feeds a large share of the grey market. If a seller can't speak to where its API comes from, or whether that manufacturer appears on the FDA's Green List, that's a sourcing question worth taking seriously — not a technicality.
The names it hides behind
Grey-market tirzepatide rarely calls itself tirzepatide on the invoice. The FDA's August 24, 2026 warning letters to five online peptide sellers list the coded product names the agency found on their sites: “GLP-1 S” or “GLP-1 Sema” for semaglutide, “GLP-2 T” or “GLP-2 Tirz” for tirzepatide, “GLP-3 Reta” or “GLP-3 RT” for retatrutide. The letters also explain why the “research use only” label does not work as a legal shield: the FDA looked at what the sites actually did, including selling bacteriostatic water as a “reconstitution solution” and publishing dosing calculators, and concluded the products were intended for human injection. In the FDA's words, “despite statements on your product labeling marketing your products ‘for research use only’ and ‘not for human or veterinary use,’ evidence obtained from your website establishes that your products are intended to be drugs for human use.”
Two points follow from that. First, the spelling you search (“grey market” or “gray market”) and the nickname on the vial change nothing about what you are holding. Second, a seller that renames tirzepatide to avoid the word is telling you, in its own way, that it knows it cannot sell tirzepatide to you. For what happened after two people who used “research use only” retatrutide died, see our October 2026 report on the FDA adverse-event reports.
Why the Distinction Matters (FDA's Position)
The FDA has been direct about the baseline risk of compounded drugs generally. In its alert on dosing errors associated with compounded semaglutide and tirzepatide products, the agency states that compounded drugs pose a higher risk to patients than FDA-approved drugs because compounded drugs do not undergo FDA premarket review for safety, quality, or effectiveness. That statement applies to all compounded medication — including compounding done correctly, by a licensed pharmacy, under a valid prescription.
Grey-market product carries a materially higher layer of risk on top of that baseline, because it strips away the safeguards that licensed compounding still provides: a pharmacist reviewing the preparation, a clinician confirming the prescription is appropriate for that patient, a state board of pharmacy that can inspect the facility, and a manufacturer of record for the API. The FDA's own overview of its concerns with unapproved GLP-1 drugs used for weight loss is explicit that products from unregistered or unlicensed sources have been found with incorrect ingredients, contamination, or significantly different potency than labeled — problems that licensed-pharmacy oversight exists specifically to catch.
The core distinction, in one sentence: licensed compounding is not FDA-approved, but it operates inside a known, inspectable regulatory system with a pharmacist and a prescription in the loop. Grey-market product operates outside that system entirely.
Already Using Grey-Market Tirzepatide? The Safer Route
A lot of people reading this are not deciding whether to buy; they already have a vial in the fridge and a dose schedule from a group chat. If that is you, the goal is not to shame you into stopping cold. It is to get a licensed clinician and a licensed pharmacy back into the loop, which is the only way anyone becomes accountable for what you are injecting. Here is what that looks like in practice.
- Do not inject a vial you cannot identify. The FDA's consumer alert says illegally marketed semaglutide and tirzepatide may be counterfeit and may contain the wrong ingredient, too little, too much, or no active ingredient at all. If the vial has no pharmacy name, no lot number and no beyond-use date, nobody can tell you what is in it.
- Keep the vial, the label and the order record. If you have had a reaction, your clinician can report it to FDA MedWatch. Even without a reaction, the record helps the clinician understand what you were actually taking.
- Tell the clinician the truth about what you used. How much, how often, for how long, and from what kind of source. Clinicians who work in this space hear it every week. A clinician who does not know your history cannot make a safe decision about your dose.
- Expect the clinician, not the vial, to set the dose. Do not assume the milligrams printed on a grey-market label equal a prescribed dose. The FDA's dosing-error alert documents mislabeled strength and unit confusion in unapproved products. The clinician may continue, lower, or restart your dose based on your history and your current response; that decision is theirs to make.
- Expect a real intake, and expect the possibility of a no. A licensed program reviews your history and can decline to prescribe. That is the feature you are paying for. A program that approves everyone is operating a checkout form, not a practice.
- Check the price against the conditions, not the headline. Licensed care costs more than a grey-market vial because a clinician, a pharmacist and a licensed pharmacy are each doing work. What it should not include is a membership fee, an auto-renewing charge, or a price that jumps when your dose goes up. The Real-Price Index lists what licensed telehealth programs actually charge and under what conditions.
At SkinnyVIP, this is a common intake scenario. You can order a single month of compounded tirzepatide for $350, with no commitment and nothing that renews, and a U.S.-licensed clinician reviews your prior use at intake. If the clinician prescribes, the pharmacy that fills it is named on your prescription so you can verify it. If the clinician does not prescribe, the price is refunded. The three-month plan is $695, about $232 per month effective, at any dose. Compounded medications are not FDA-approved products, and a prescription is never guaranteed.
How to Identify a Licensed Compounding Pharmacy
This is the practical part. Six checkpoints that separate a licensed compounding pharmacy from everything else, in order of how quickly you can check them.
- Requires a valid prescription from a U.S.-licensed clinician. No prescription review, no legitimate compounded product. This is the single fastest filter.
- Names the compounding pharmacy on the label. A licensed pharmacy has nothing to hide and identifies itself. If the label or paperwork never names an actual pharmacy, there is no pharmacy of record to verify.
- Holds a current state-board license that you can verify. Every state board of pharmacy maintains a public license lookup. A named pharmacy should show up, in good standing, in the state where it's licensed.
- Operates as either a 503A or 503B facility — and you can tell which. 503A pharmacies compound patient-specific prescriptions; 503B outsourcing facilities are FDA-registered and compound at larger scale. A legitimate provider can tell you which category applies and back it up.
- Describes its compounded product accurately, without brand-equivalence claims. A licensed pharmacy describes its compounded product accurately as a compounded preparation and does not claim FDA approval or equivalence to any brand-name drug.
- Does not import API from unverified foreign sources. A pharmacy operating in good standing sources its active pharmaceutical ingredient from manufacturers that meet FDA sourcing standards, not from unregistered overseas suppliers.
Red Flags of Grey-Market Vendors
The FDA's warning-letter record over the past year points to a consistent pattern of grey-market red flags. None of these require special expertise to spot — they're visible on the seller's own website, before you ever place an order.
- “For research use only” or similar disclaimers on a product being marketed and sold for injection into a human body.
- No prescription requirement — checkout proceeds with no clinician review of any kind.
- No clinician review at any point in the ordering process, even a cursory one.
- No pharmacy identification on the label or in the order paperwork — nothing to verify against a state board of pharmacy.
- Pricing dramatically below the licensed compounding market rate, with no clear explanation for the gap.
- Foreign shipping origins for a product being sold as a U.S. pharmacy preparation.
These are the same patterns the FDA has referenced across its warning-letter enforcement framework, tracked on the agency's compounding inspections, recalls, and other actions index. The goal here isn't to name and shame individual sellers — it's to recognize the pattern regardless of which vendor happens to be running it.
“Grey Market Zepbound” or “Grey Market Mounjaro” Is a Different Problem
Some people searching this topic are not looking at compounded or “research” vials at all. They have been offered a brand-name Zepbound® or Mounjaro® pen on social media, in a gym, or through a friend of a friend, often described as “extra” or “leftover” from someone's prescription. That is not a grey market in the compounding sense; it is either diverted product or a counterfeit.
Eli Lilly's 2026 open letter is blunt about it: “Any Mounjaro® or Zepbound® offered for purchase on social media is unlawful,” and such products “are either fake or being ‘resold’ by an individual who obtained them through some other means.” Lilly also states that it is the only lawful supplier of FDA-approved tirzepatide medicines in the United States, that it does not supply tirzepatide ingredient to compounding pharmacies, and that products it has tested from unauthorized sources have contained bacteria, high impurity levels, or, in at least one case, nothing but sugar alcohol. A genuine Zepbound or Mounjaro pen comes from a licensed pharmacy with a prescription, a pharmacy label and a Lilly lot number. Anything else is not that product, whatever the box looks like. If you believe you have a fake, Lilly asks that it be reported to the Lilly Answers Center at 1-800-545-5979, and the FDA asks that it be reported through MedWatch.
SkinnyVIP is not affiliated with Eli Lilly and does not sell Zepbound® or Mounjaro®. Compounded tirzepatide is a separate, non-FDA-approved product prepared by a licensed compounding pharmacy.
What the FDA Has Been Doing (2025–2026 Enforcement Timeline)
The FDA has sent at least four waves of warning letters targeting misleading or unapproved GLP-1 claims since late 2025, and has tightened the import rules twice. A brief factual timeline, most recent at the bottom:
The consistent thread across these waves is misleading marketing — primarily claims of FDA approval or brand equivalence that the products don't have, and sourcing practices that fall outside the licensed compounding system. The full FDA compounding-actions index is the best way to check on any specific enforcement history.
7 Questions to Ask Before You Order Compounded GLP-1
For the pharmacy-specific version of these questions, including how to read a certificate of analysis and check inspection history, see the 7-point pharmacy-vetting checklist.
Use this checklist before you order from any provider — telehealth platform, med spa, or direct-to-consumer website.
- Is there a real prescription review by a U.S.-licensed clinician? Not a form you fill out that auto-approves — an actual clinical review tied to your history.
- What compounding pharmacy is on the label — and can you verify their state license? Get the pharmacy name and check it against the relevant state board of pharmacy lookup.
- Is the product labeled “for research use only” or anything similar? That language on a product being sold for human use is a serious red flag, not boilerplate.
- Does the seller claim their product is “FDA-approved” or equivalent to any brand-name GLP-1? The FDA has issued warning letters over exactly this kind of claim.
- Where is the API sourced — is the manufacturer on the FDA's Green List? A legitimate pharmacy should be able to answer this without hesitation.
- Is there a licensed U.S. address for the pharmacy and the clinical practice? Both should be verifiable, not a P.O. box or an address that doesn't match the state license.
- What's the pharmacy's inspection history? The FDA's compounding inspections, recalls, and other actions page is a starting point for checking whether a facility has any documented history worth knowing about.
If you can't get a straight answer to any of these seven questions within a normal conversation, treat that as the answer.
How SkinnyVIP Handles This
SkinnyVIP is a physician-led telehealth practice. Prescriptions are written by U.S.-licensed clinicians for individual patients, based on an actual clinical review. Compounded semaglutide and tirzepatide are prepared by licensed compounding pharmacies under physician supervision, and the pharmacy is identified on your prescription so it can be verified. If you are currently using a grey-market product, say so at intake; the clinician's dose decision depends on it, and the section above explains what to expect. Compounded medications are not FDA-approved products. Individual results vary.
If you want to see how the clinical and prescribing process actually works, how SkinnyVIP's compounded tirzepatide program works walks through it in detail, and the flat, no-membership pricing page lays out the full cost with nothing hidden in a separate membership fee. For a broader look at how compounded GLP-1 pricing compares across telehealth providers, see the full 2026 compounded GLP-1 pricing comparison.
SkinnyVIP is not affiliated with Novo Nordisk (Ozempic®/Wegovy®) or Eli Lilly (Mounjaro®/Zepbound®).